CTLA4 and breast cancer: Associations with TNBC subtype, chemotherapy response, and 6-month progression-free survival (PFS) were evaluated.<h4>Results</h4>Seven immune checkpoint proteins (LAG-3, BTLA, CD80, GITRL, CTLA-4, GITR, TLR-2) showed significant differential expression between BC patients and controls.